CN Patent

CN104666238A — 稳定性提高的(z)-2-氰基-3-羟基-丁-2-烯酸-(4’-三氟甲基苯基)-酰胺片剂制剂

Assigned to Sanofi Aventis Deutschland GmbH · Expires 2015-06-03 · 11y expired

What this patent protects

本发明涉及包含(Z)-2-氰基-3-羟基-丁-2-烯酸-(4’-三氟甲基苯基)-酰胺的固体药物组合物；涉及其制备方法；涉及使用所述组合物治疗罹患自身免疫疾病，特别是系统性红斑狼疮或慢性移植物抗宿主病、多发性硬化或类风湿性关节炎的受试者的方法。

USPTO Abstract

本发明涉及包含(Z)-2-氰基-3-羟基-丁-2-烯酸-(4’-三氟甲基苯基)-酰胺的固体药物组合物；涉及其制备方法；涉及使用所述组合物治疗罹患自身免疫疾病，特别是系统性红斑狼疮或慢性移植物抗宿主病、多发性硬化或类风湿性关节炎的受试者的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN104666238A
Jurisdiction
CN
Classification
—
Expires
2015-06-03
Drug substance claim
No
Drug product claim
No
Assignee
Sanofi Aventis Deutschland GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.